Neurotez

Neurotez

Early Stage

Neurotez Inc. is developing a drug to treat Leptin deficiency in Alzheimer’s patients.

Neurotez Inc. is developing a drug to treat Leptin deficiency in Alzheimer’s patients.

Overview

Raised to Date: Raised: $33,845

Total Commitments ($USD)

Platform

StartEngine

Start Date

11/08/2021

Close Date

03/09/2022

Min. Goal
$10,000
Max. Goal
$281,096
Min. Investment

$496

Security Type

Equity - Common

Series

Pre-Seed

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$4.00

Pre-Money Valuation

$44,870,036

Rolling Commitments ($USD)

Status
Funded
Reporting Date

03/30/2022

Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$280

# of Investors

32

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2005

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2B2C

Margin

Low

Capital Intensity

High

Location

Bridgewater, New Jersey

Business Type

Growth

Neurotez, with a valuation of $44.9 million, is raising funds on StartEngine. The company is developing a hormone replacement therapy named Memtin to treat Leptin deficiency in Alzheimer’s patients. The drug will help slow down the cognitive decline in Alzheimer’s patients and other forms of dementia. Neurotez has already received many rewards and recognitions and is backed by an excellent team of experts. Nikolaos Tezapsidis founded Neurotez in 2005. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $281,096. The campaign proceeds will be used for the execution and delivery of data from its Phase 1B trial.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$9,115

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-188,407

$-367,295

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$5,882

$283

Accounts Receivable

$0

$0

Total Assets

$164,744

$176,536

Short-Term Debt

$420,466

$396,332

Long-Term Debt

$0

$26,000

Total Liabilities

$420,466

$422,332

Financials as of: 11/08/2021
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Neurotez 01/26/2023 Netcapital $45,272,228 $15,952 Equity - Common Funded RegCF
Neurotez 03/09/2022 StartEngine $44,870,036 $33,845 Equity - Common Funded RegCF
Neurotez 06/23/2021 Netcapital $21,959,058 $255,718 Equity - Common Funded RegCF
Neurotez 02/25/2018 Netcapital $24,544,690 $95,809 Equity - Common Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.

Create your first portfolio

Create your own startup investment portfolio on KingsCrowd.

Track all of your startup investments in one place using our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Neurotez on StartEngine 2021
Platform: StartEngine
Security Type: Equity - Common
Valuation: $44,870,036
Price per Share: $4.00

Follow company

Follow Neurotez on StartEngine 2021

Buy Neurotez's Deal Report

Warning: according to the close date for this deal, Neurotez may no longer be accepting investments.

Neurotez Deal Report

Get KingsCrowd’s comprehensive report on Neurotez including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Neurotez is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Neurotez deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge